div class=trans-pagebuttonPage 1button div class=trans-image amp-img class=trans-thumb alt=Page 1: A New Ink On Pharma Life A Quarterly News Letter from Dept · diabetes January 25 2013 -- Oseni alogliptin and pioglitazone is a dipeptidyl peptidase-4 DPP-4 inhibitor and src=https:reader030fdocumentsnetreader030viewer20220406055ea963c5a092d923cc000147html5thumbnails1jpg width=142 height=106 layout=responsive amp-img divdivdiv class=trans-pagebuttonPage 2button div class=trans-image amp-img class=trans-thumb alt=Page 2: A New Ink On Pharma Life A Quarterly News Letter from Dept · diabetes January 25 2013 -- Oseni alogliptin and pioglitazone is a dipeptidyl peptidase-4 DPP-4 inhibitor and src=https:reader030fdocumentsnetreader030viewer20220406055ea963c5a092d923cc000147html5thumbnails2jpg width=142 height=106 layout=responsive amp-img divdivdiv class=trans-pagebuttonPage 3button div class=trans-image amp-img class=trans-thumb alt=Page 3: A New Ink On Pharma Life A Quarterly News Letter from Dept · diabetes January 25 2013 -- Oseni alogliptin and pioglitazone is a dipeptidyl peptidase-4 DPP-4 inhibitor and src=https:reader030fdocumentsnetreader030viewer20220406055ea963c5a092d923cc000147html5thumbnails3jpg width=142 height=106 layout=responsive amp-img divdivdiv class=trans-pagebuttonPage 4button div class=trans-image amp-img class=trans-thumb alt=Page 4: A New Ink On Pharma Life A Quarterly News Letter from Dept · diabetes January 25 2013 -- Oseni alogliptin and pioglitazone is a dipeptidyl peptidase-4 DPP-4 inhibitor and src=https:reader030fdocumentsnetreader030viewer20220406055ea963c5a092d923cc000147html5thumbnails4jpg width=142 height=106 layout=responsive amp-img divdivdiv class=trans-pagebuttonPage 5button div class=trans-image amp-img class=trans-thumb alt=Page 5: A New Ink On Pharma Life A Quarterly News Letter from Dept · diabetes January 25 2013 -- Oseni alogliptin and pioglitazone is a dipeptidyl peptidase-4 DPP-4 inhibitor and...